Pfizer's JAK inhibitor clears second pivotal eczema study, but can it topple Regeneron's Dupixent?
The atopic dermatitis market is crowded. Dupixent, from Regeneron and Sanofi, may be king of the arsenal of therapies to combat eczema — but various drugmakers big and small are out to usurp its throne. Pfizer on Friday made its pitch, with a second slate of positive late-stage data on its experimental drug, abrocitinib.
Abrocitinib belongs to a class of drugs called Janus kinase (JAK) inhibitors — which have been plagued with safety concerns. Named after the two-faced Roman God Janus, the family consists of four enzymes: JAK1, JAK2, JAK3 and TYK2, which are associated with cytokine receptors on the surface of cells and form part of a pathway involved in inflammatory and immune responses.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
